PO&T Commercial Asset Development Lead

Location/Type: Hybrid (Cambridge, MA or Baar, Switzerland) Responsibilities Oversee development and implementation of a 5-year PO&T Asset Strategy and maintain an 18-month rolling Tactical Plan aligned to company objectives. Lead the cross-functional PO&T Asset Team across PO&T Line Functions to execute the Asset Strategy/Tactical Plan. Serve as PO&T liaison to R&D Program teams and PDC teams to support asset(s). Manage conflicts related to Asset Strategy in consultation with the PO&T Governance Committee. Track and assess asset impacts on COGS, E&O, and OPEX; develop improvement strategies with Line Functions. Develop business cases for significant asset initiatives and obtain PO&T Governance Committee endorsement/approval. Qualifications BS or equivalent in Sciences/Engineering with an advanced degree (MS/PhD/MBA) preferred in a relevant biopharmaceutical discipline. 12+ years of experience with matrix management. Proven matrix leadership across full product lifecycle program teams (e.g., CMC/PO&T sub-teams). Alliance management experience (preferably global), including understanding of business contracts. Experience with CMC, supply chain, and/or LCM development from IND to NDA/BLA; strong knowledge of global registration processes. Healthcare/biotech/pharmaceutical industry experience; understanding of cross-functional interdependencies (R&D, commercial, technical development, regulatory). Strategic, organizational, relationship‑building, and political skills; ability to lead/influence without authority. Strong communication, negotiation, problem‑solving, and decision‑making. Ability to identify critical program risks and develop mitigation plans. Benefits Medical, dental, vision, life. Fitness/wellness reimbursement. Short‑ and long‑term disability. 15+ paid vacation plus end‑of‑year shutdown (Dec26–Dec31). Up to 12 paid holidays + 3 personal days. Sick time. Paid maternity/parental leave. 401(k) with match. Employee stock purchase plan. Tuition reimbursement up to $10,000/year. Employee Resource Groups participation. #J-18808-Ljbffr Scorpion Therapeutics